Levi & Korsinsky notifies investors that it has commenced an investigation into Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) concerning potential violations of the federal securities laws.
Syros issued a press release on August 12, 2024, "announcing that it will discontinue enrollment in the SELECT-AML-1 Phase 2 clinical trial evaluating the triplet regimen of tamibarotene in combination with venetoclax and azacitidine compared to the doublet regimen of venetoclax and azacitidine in newly diagnosed, unfit patients with acute myeloid leukemia (AML) and RARA gene overexpression." The Company stated that its "decision is based on the results of a prespecified interim analysis of the trial," following which the Syros determined that "the probability for success . . . to demonstrate superiority at the final analysis . . . was considered low[.]" Following this news, Syros's stock price fell over 61% on August 13, 2024.
If you suffered a loss on your Syros Pharmaceuticals securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure





